Sanara MedTech (NASDAQ:SMTI) and Kewaunee Scientific (NASDAQ:KEQU) Financial Analysis

Kewaunee Scientific (NASDAQ:KEQU – Get Free Report) and Sanara MedTech (NASDAQ:SMTI – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, risk, earnings, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Kewaunee Scientific and Sanara MedTech, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kewaunee Scientific 0 1 0 0 2.00
Sanara MedTech 1 4 0 0 1.80

Sanara MedTech has a consensus target price of $35.00, indicating a potential downside of 0.40%. Given Sanara MedTech’s higher possible upside, analysts clearly believe Sanara MedTech is more favorable than Kewaunee Scientific.

Insider & Institutional Ownership

32.7% of Kewaunee Scientific shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 14.1% of Kewaunee Scientific shares are held by insiders. Comparatively, 42.0% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Kewaunee Scientific has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Profitability

This table compares Kewaunee Scientific and Sanara MedTech’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kewaunee Scientific 2.97% 11.61% 4.82%
Sanara MedTech -29.15% 29.72% 2.84%

Valuation and Earnings

This table compares Kewaunee Scientific and Sanara MedTech”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Kewaunee Scientific $282.00 million 0.35 $9.62 million $2.76 12.48
Sanara MedTech $103.12 million 3.13 -$37.56 million ($3.59) -9.79

Kewaunee Scientific has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Summary

Kewaunee Scientific beats Sanara MedTech on 8 of the 13 factors compared between the two stocks.

About Kewaunee Scientific

(Get Free Report)

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The company's laboratory products are used in chemistry, physics, biology, and other general science laboratories in the pharmaceutical, biotechnology, industrial, chemical, commercial, educational, government, and health care markets; and technical products are used in facilities manufacturing computers and light electronics and by users of computer and networking furniture. It sells its products primarily through dealers, its subidiaries, and a national distributor. The company was founded in 1906 and is headquartered in Statesville, North Carolina.

About Sanara MedTech

(Get Free Report)

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Receive News & Ratings for Kewaunee Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kewaunee Scientific and related companies with MarketBeat.com's FREE daily email newsletter.